Page last updated: 2024-10-24

cranial skeletal system development

Definition

Target type: biologicalprocess

The process whose specific outcome is the progression of a cranial skeletal system over time, from its formation to the mature structure. The cranial skeletal system is the skeletal subdivision of the head, and includes the skull (cranium plus mandible), pharyngeal and/or hyoid apparatus. [GO_REF:0000094, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11262227]

Cranial skeletal system development is a complex and intricate process that begins during embryonic development and continues throughout childhood. It involves the coordinated action of multiple cell types and signaling pathways, ultimately resulting in the formation of the skull, which protects the brain and provides attachment points for facial muscles.

The process can be broadly divided into two phases:

**1. Neural Crest Cell Migration and Differentiation:**

* During early embryonic development, neural crest cells, a migratory population of multipotent cells, arise from the neural tube. These cells migrate extensively throughout the developing embryo, contributing to various structures, including the craniofacial skeleton.
* Specific populations of neural crest cells migrate to the head region, where they differentiate into chondrocytes (cartilage-producing cells) and osteoblasts (bone-producing cells), which are essential for the formation of the cranial skeleton.
* These cells are guided by specific signaling pathways, including FGF, Wnt, and BMP, which regulate their proliferation, migration, and differentiation.

**2. Cartilage and Bone Formation:**

* The initial craniofacial skeleton is formed by cartilage, a flexible and resilient tissue. This cartilaginous template serves as a scaffold for the later formation of bone.
* Chondrocytes within the cartilage produce a specialized extracellular matrix, rich in collagen and proteoglycans, providing structural support.
* As development progresses, the cartilaginous template undergoes endochondral ossification, a process by which cartilage is gradually replaced by bone.
* Osteoblasts, derived from neural crest cells, deposit bone matrix, which mineralizes to form the bony skull.
* The process of intramembranous ossification also contributes to cranial bone formation. This process involves the direct deposition of bone matrix by osteoblasts without a prior cartilaginous template.
* Various signaling pathways, including TGF-beta, IGF, and PTH, regulate the balance between cartilage formation and bone formation.

**3. Growth and Remodeling:**

* Throughout childhood, the cranial skeleton undergoes significant growth and remodeling.
* The growth plates within the bones contribute to their elongation.
* Osteoblasts and osteoclasts, specialized cells that respectively deposit and resorb bone, continuously remodel the skull in response to mechanical forces and growth signals.
* This remodeling process ensures that the skull can accommodate the growing brain and other facial structures.

**4. Craniofacial Syndromes:**

* Disruptions in any of the developmental steps outlined above can lead to craniofacial syndromes, characterized by abnormalities in the skull and facial features.
* These syndromes often result from genetic mutations affecting specific signaling pathways or transcription factors involved in cranial skeletal development.

The development of the cranial skeletal system is a complex and highly regulated process involving the interplay of multiple cellular and molecular mechanisms. Understanding these mechanisms is crucial for understanding craniofacial disorders and for developing potential therapies.
'"

Proteins (3)

ProteinDefinitionTaxonomy
Catenin beta-1A catenin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P35222]Homo sapiens (human)
Guanine nucleotide-binding protein subunit alpha-11A guanine nucleotide-binding protein subunit alpha-11 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P29992]Homo sapiens (human)
Endothelin-1 receptorAn endothelin-1 receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25101]Homo sapiens (human)

Compounds (52)

CompoundDefinitionClassesRoles
amiodaroneamiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound
cardiovascular drug
avaproirbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
azaspiro compound;
biphenylyltetrazole
angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
mianserinmianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.

Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
propranololpropranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
naphthalenes;
propanolamine;
secondary amine
anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
sulfathiazolesulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.

Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.
1,3-thiazoles;
substituted aniline;
sulfonamide;
sulfonamide antibiotic
antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfisoxazolesulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.

Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
isoxazoles;
sulfonamide;
sulfonamide antibiotic
antibacterial drug;
drug allergen
salvinsalvin: a biocyclic diterpenoid; from sage and rosemary (Lamiaceae)abietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite
toxoflavintoxoflavin : A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7.

toxoflavin: azapteridine antibiotic; structure
carbonyl compound;
pyrimidotriazine
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor
bosentan anhydrousBosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.primary alcohol;
pyrimidines;
sulfonamide
antihypertensive agent;
endothelin receptor antagonist
1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)-1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-: an ET(A) and ET(B) endothelin receptor antagonist; structure in first source
ro 46-2005Ro 46-2005: an orally active non-peptide antagonist of endothelin receptors; structure given in first source
pd 142893PD 142893: functional antagonist of endothelin-stimulated vasoconstriction
5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide: structure in first source; endothelin receptor antagonistnaphthalenes;
sulfonic acid derivative
tak 044TAK 044: endothelin receptor antagonist
endothelin (16-21)endothelin (16-21): C-terminal hexapeptide of endothelin; amino acid seq. given in first sourcepeptide
tezosentantezosentan: structure in first source
bms 207940N-((2'-(((4,5-dimethyl-3-isoxazolyl)amino)sulfonyl)-4-(2-oxazolyl)(1,1'-biphenyl)-2-yl)methyl)-N,3,3-trimethylbutanamide: an ET(A) receptor antagonist; structure in first source
atrasentanAtrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.pyrrolidines
lu 135252
enrasentanenrasentan : A member of the class of indanes that is 2,3-dihydro-1H-indene which is substituted by a 1,3-benzodioxol-5-yl group, carboxy group, 2-(2-hydroxyethoxy)-4-methoxyphenyl group and a propoxy group at positions 1S, 2R, 3S and 5, respectively. It is an orally active mixed endothelin A/B receptor antagonist with a 100-fold greater affinity for the endothelin A receptor. The drug was being developed by GSK for the treatment of congestive heart failure and pulmonary hypertension (clinical trials discontinued).

enrasentan: decreases ischemic brain injury; an endothelin A and B receptor antagonist; structure in first source
aromatic ether;
benzodioxoles;
indanes;
monocarboxylic acid;
monomethoxybenzene;
primary alcohol
antihypertensive agent;
endothelin receptor antagonist
2-[(4,6-dimethyl-2-pyrimidinyl)oxy]-3-methoxy-3,3-diphenylpropanoic aciddiarylmethane
tbc-11251sitaxsentan: endothelin A receptor antagonist; structure in first sourcebenzodioxoles
cercosporincercosporin : An organic heterohexacyclic compound that is perylo[1,12-def][1,3]dioxepine-6,11-dione substituted by hydroxy groups at positions 5 and 12, by methoxy groups at positions 7 and 10, and by 2-hydroxypropyl groups at positions 8 and 9 (the R,R-stereoisomer). It is a phytotoxin which was first isolated from the pathogenic soybean fungus, Cercospora kikuchii and later found in multiple members of the genus Cercospora.

cercosporin: phyytotoxin from Cercospora beticola Sacc; posses photodynamic action on mice, bacteria & plants
bq 123cyclo(Trp-Asp-Pro-Val-Leu): derived from the modification of a natural lead of BE-18257B, an endothelin A receptor antagonist; has neuroprotective activity; amino acid sequence given in first sourcecyclic peptide
LSM-42773aromatic ketone
etodolac, (-)-isomer(R)-etodolac : The R-enantiomer of etodolac. It is inactive, in contrast to the enantiomer, (S)-etodolac, which is a preferential inhibitor of cyclo-oxygenase 2 and a non-steroidal anti-inflammatory. The racemate is commonly used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain.etodolac
a 192621A 192621: ET(B) receptor antagonist
irl 2500IRL 2500: Endothelin-B receptor antagonist; structure in first source
ro 46-8443Ro 46-8443: a non-peptide endothelin ET(B) receptor selective antagonist; structure given in first source
sulindac sulfonesulindac sulfone : A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.

sulindac sulfone: inhibits K-ras-dependent cyclooxygenase-2; sulfated analog of indomethacin;; CP248 is an antineoplastic agent that fosters microtubule depolymerization; structure in first source
monocarboxylic acid;
organofluorine compound;
sulfone
apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ro 47-8634Ro 47-8634: structure in first source
clazosentanclazosentan: endothelin A receptor antagonist used for cerebral vasospasm; structure in first source;
lu 224332felotaxel: an antineoplastic agent; structure in first source
lu 208075ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertensiondiarylmethane
bms 193884
ci 1020
lu 302872LU 224332: endothelin-A/B receptor antagonist
bms 248360
zibotentanZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferationphenylpyridine
avosentanAvosentan: structure in first source
ym-254890YM-254890: structure in first source
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride
ucn 1028 ccalphostin C: structure given in first source; isolated from Cladosporium cladosporioides
naluzotannaluzotan: an antidepressant and anti-anxiety agent; structure in first source
FR900359FR900359: G-protein inhibitor from Ardisia crenata sims that shows inhibition of platelet aggregation and decrease of blood pressurecyclodepsipeptide
macitentanaromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides
antihypertensive agent;
endothelin receptor antagonist;
orphan drug
a 803467A 803467: an Nav1.8 sodium channel blocker; structure in first source
endothelin-1Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)
pd 156707
act-132577ACT-132577 : A member of the class of sulfamides in which one of the amino groups of sulfonamide is substituted by a 5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl group. An active metabolite of macitentan (obtained by oxidative depropylation), an orphan drug used for the treatment of pulmonary arterial hypertension.

aprocitentan: a macitentan metabolite
aromatic ether;
organobromine compound;
pyrimidines;
sulfamides
antihypertensive agent;
drug metabolite;
endothelin receptor antagonist;
xenobiotic metabolite
endothelins
nitd 609NITD 609: an antimalarial and coccidiostat; structure in first source